Abstract: The invention provides a molecule that modulates an activity of a Src family kinase for use in preventing or treating a metastatic cancer a subject. Preferably, the molecule comprises or consists of the structure: Bj-[(Pro)n-Xr-His-Pro-His-Ala-Arg-Ile-Lys]m-Rp, or Bj-[lys-ile-arg-ala-his-pro-his-xr-(pro)n]m-Rp, or a derivative or fragment thereof, wherein B is a first chemical moiety, j is 0 or 1, n is an integer from 1-10, X is any amino acid, r is an integer from 0 to 2, m is an integer from 1 to 3, R is a second chemical moiety, p is 0 or 1, and [lys-ile-arg-ala-his-pro-his-xr-(pro)n] is the retro-inverso peptide of [(Pro)n-Xr-His-Pro-His-Ala-Arg-Ile-Lys].

Abstract: The present invention generally relates to a method for preparing structurally unique nanomaterials and the products thereof. In particular, the present invention discloses a method for preparing ultra-narrow nanowire or nanorod on a patterned monolayer or thin film supported by a 2D material substrate in a nonpolar environment, wherein said pattered monolayer or thin film comprises a polymerizable phospholipid with a terminal amine. A gold nanowire or nanorod so prepared has a highly controlled diameter of about 2 nm, and a length about 1000 nm, dependent in part on molecular domain sizes in the monolayer.

Abstract: A polyester composition includes polybutylene terephthalate and an aliphatic-aromatic copolyester. Based on the total weight of the polybutylene terephthalate and the aliphatic-aromatic copolyester, the content of the polybutylene terephthalate is from 50 to 99% by weight, and the content of the aliphatic-aromatic copolyester is from 1 to 50% by weight. Further, a method for preparing such a polyester composition and a toughened composite material prepared therefrom. The polyester composition has an elongation at break of up to 230% or more, and an improved toughness without substantial loss of strength.

Abstract: In certain embodiments, the present invention provides the use of microRNA (miR)-200a to inhibit ossification and bone formation.

Abstract: Methods of treatment of MIF-related diseases and methods of MIF inhibition are provided.

Abstract: Methods of expressing an expression product of interest are provided. Accordingly there is provided a method comprising introducing into a cell a polynucleotide comprising an AimR responsive element operatively linked to a nucleic acid sequence encoding the expression product of interest, and contacting said cell with an AimP peptide comprising an amino acid sequence of XXXXGG/A, wherein said AimP peptide is capable of binding said AimR polypeptide and dissociating said AimR polypeptide from said AimR responsive element. Also provided are articles of manufacture, isolated peptides, polynucleotides and nucleic acid constructs.

Abstract: A semiconductor device includes a gate electrode extending in a first direction on a substrate, a first active pattern extending in a second direction intersecting the first direction on the substrate to penetrate the gate electrode, the first active pattern including germanium, an epitaxial pattern on a side wall of the gate electrode, a first semiconductor oxide layer between the first active pattern and the gate electrode, and including a first semiconductor material, and a second semiconductor oxide layer between the gate electrode and the epitaxial pattern, and including a second semiconductor material. A concentration of germanium of the first semiconductor material may be less than a concentration of germanium of the first active pattern, and the concentration of germanium of the first semiconductor material may be different from a concentration of germanium of the second semiconductor material.

Abstract: The present invention relates to a self assembled catalyst. More particularly, the present invention relates to a self-assembled catalyst of formula (I) comprising supramolecular phosphine and carboxylate ligands, process for preparation thereof and use of said catalyst of formula (I) in olefin polymerization.

Abstract: A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver.

Abstract: The present invention relates to a composition for preventing or treating obesity containing an ethanolic extract of Ramulus mori as an active ingredient. As the present invention contains an ethanolic extract of Ramulus mori, extracted from natural substance Ramulus mori, as an active ingredient, the present invention may prevent or treat obesity by inhibiting lipid accumulation in adipocytes without any side effects to a human body and inhibiting preadipocytes from being differentiated into adipocytes.

Abstract: In an embodiment, a network system comprises a plurality of nodes and a plurality of optical amplifiers. A first node comprises a first transmitter configured to send a wavelength-division-multiplexed optical signal and a first receiver configured to receive a wavelength-division-multiplexed optical signal, and the second node comprises a second transmitter configured to send a wavelength-division-multiplexed optical signal and a second receiver configured to receive a wavelength-division-multiplexed optical signal. The first transmitter and the second transmitter are optically connected to an input of the first optical amplifier and an input of the second optical amplifier, respectively, and the first receiver and the second receiver are optically connected to an output of the first optical amplifier and an output of the second optical amplifier, respectively. Each of the first photoreceiver and the second photoreceiver comprises a photoreceiver and a reception circuit.

Abstract: The present disclosure provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, e.g. cancer, benign tumor, etc.). Related materials and methods are also provided herein.

Abstract: Systems and methods for ultrafast synthetic transmit aperture (“USTA”) ultrasound imaging using coded virtual sources are described. The methods can implement spatially distinct or spatially overlapping sub-apertures with appropriate timing of transmission between the spatially overlapping sub -apertures. The systems and methods described here are capable of increasing signal-to-noise ratio (“SNR”) and spatial resolution to reduce frame rate.

Abstract: Disclosed is a biochemical detection device in which a reaction incubation time required for a biomolecular reaction in a liquid-phase based point-of-care detection reaction device is passively controlled using a dissolvable material layer in a limited volume, thereby to minimize the user intervention. The biochemical detection device includes a substrate; a probe disposed on the substrate; a dissolvable material layer disposed on the substrate, wherein the dissolvable material layer has a first opening defined therein, wherein the probe is received in the first opening; an absorbing material layer disposed on the dissolvable material layer and having a second opening defined therein, wherein the first opening communicates with the second opening and is smaller than the second opening; and a non-dissolvable material layer disposed on an inner face of the second opening of the absorbing material layer and on an exposed top face of the dissolvable material layer.

Abstract: This document relates to devices and methods for the treatment of heart conditions. For example, this document provides devices and methods for treating heart failure with preserved ejection fraction, including diastolic heart failure, by performing a pericardial modification procedure.

Abstract: Microorganisms that co-consume glucose with non-glucose carbohydrates, such as xylose, and methods of using same. The microorganisms comprise modifications that reduce or ablate the activity of a phosphoenolpyruvate (PEP):carbohydrate phosphotransferase system (PTS) protein or modifications that reduce or ablate the activity of a phosphoglucose isomerase and a GntR. The PTS protein may be selected from an enzyme I (EI), an HPr, an FPr, and an enzyme IIGlc (EIIGlc). Additional modifications include reduction or ablation of the activity of a pyruvate formate lyase, a lactate dehydrogenase, and a fumarate reductase and inclusion of recombinant pyruvate decarboxylase and alcohol dehydrogenase genes. The microorganisms are particularly suited to co-consuming glucose and xylose in media containing these substrates and producing ethanol therefrom.

Abstract: An apparatus for receiving a signal through an unlicensed band includes: a processor, a memory, and a radio frequency unit, wherein the processor executes a program stored in the memory to perform: receiving a secondary synchronization signal (SSS) in at least one remaining subframe except a subframe 0 or a subframe 5 of a plurality of subframes included in a discovery signal measurement timing configuration (DMTC), and detecting the SSS by using a subframe number of the subframe 0 or the subframe 5.

Abstract: One embodiment provides an implantable biomedical probe. The probe can include a substrate and one or more metallic coils positioned above the substrate. A respective metallic coil is configured to generate an electromagnetic field in response to an alternating current flowing through the metallic coil. The probe can further include a smart polymer layer positioned above the metallic coils. The smart polymer layer can include at least one photo-switching magnetic material that changes magnetic susceptibility in response to optical stimuli.

Abstract: The process comprises delivering a spray solution comprising an active agent and a matrix material in an organic solvent to a spray-drying apparatus, atomizing the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the organic solvent from the droplets to form a plurality of particles, and collecting the particles. The spray solution may be formed by forming a feed suspension comprising the active agent, the matrix material, and the organic solvent, wherein the feed suspension is at a temperature T1, and directing the feed suspension to a heat exchanger, thereby increasing the temperature of the feed suspension to a temperature T2, wherein T2 is greater than T1, and the spray solution is at a pressure greater than the vapor pressure of the organic solvent at T2, such that the active agent and matrix material are soluble in the organic solvent at T2.

Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.